Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort.
Simple Summary: In this study, we looked at medical records showing treatment patterns and outcomes in people with advanced urothelial cancer in the United States following the approval of avelumab for first-line maintenance treatment. Most people who completed first-line treatment received platinum...
| Publicado en: | Current Oncology Vol. 31; no. 3; pp. 138 - 150 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Mar2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=192598793&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 192598793 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Mar2026 vid: 31 iid: 3 pid: 97109 pub: MDPI artinfo: ui: 192598793 10.3390/curroncol33030138 192598793 ppf: 138 ppct: 12 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort. aug: au: Carson, Kenneth Mahmoudpour, Seyed Hamidreza Ike, Chiemeka Monzon, Sebastian Fragkogianni, Stamatina Kearney, Mairead affil: Department of Internal Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Arkus Professional Building, 676 N. St. Clair St. Suite 850, Chicago, IL 60611, USA sug: ab: Simple Summary: In this study, we looked at medical records showing treatment patterns and outcomes in people with advanced urothelial cancer in the United States following the approval of avelumab for first-line maintenance treatment. Most people who completed first-line treatment received platinum-based chemotherapy (66%), and 89% of these people had no evidence of disease progression. Most people who went on to receive first-line maintenance received avelumab (62%). Outcomes with avelumab maintenance were similar to previous studies. Our study also demonstrates that, after disease progression on avelumab maintenance, second-line enfortumab vedotin appears to be an effective treatment option. Overall, available data support the use of avelumab maintenance as a standard treatment in people whose disease has not progressed following first-line platinum-based chemotherapy. Further research is needed to look at additional available treatment options and their associated outcomes when received outside of a clinical trial. Background: This study describes treatment patterns and clinical outcomes in patients with advanced urothelial carcinoma (aUC) in the US following the approval of avelumab for first-line maintenance treatment. Methods: This retrospective cohort study used deidentified patient data from the Tempus database. Eligible patients had completed first-line systemic anticancer treatment for aUC between July 2020 and March 2023. Results: In total, 974 eligible patients were identified; most (72%) were male. Median age at diagnosis was 70 years. Among patients who completed first-line platinum-based chemotherapy (644 [66%]), 574 (89%) had no evidence of disease progression. Of 219 patients who received first-line maintenance, 135 (62%) received avelumab. Median (95% CI) overall survival (OS) and progression-free survival (PFS) from avelumab maintenance start were 14.9 months (13.1—not estimable [NE) and 6.4 months (4.6—NE), respectively. Enfortumab vedotin (EV) was the most common second-line treatment after avelumab (70%). Median (95% CI) OS and PFS from second-line EV start were 11.6 months (6.1—NE) and 6.6 months (4.1—NE), respectively. Conclusions: Results provide insights into the impact of avelumab first-line maintenance treatment in patients with aUC in the US. Effectiveness data are consistent with previous findings, supporting the use of avelumab maintenance in patients without disease progression following first-line platinum-based chemotherapy. Second-line EV after progression on avelumab maintenance had similar effectiveness to results from other real-world studies. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|